ArticlePediatric rheumatology online journal2018
Incidence and risk factors for recurrent Henoch-Schönlein purpura in children from a 16-year nationwide database.
Article in Pediatric rheumatology online journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Associations between lipid metabolism and Henoch-Schönlein purpura nephritis in children: a systematic review and meta-analysis.Italian journal of pediatrics · 2026Pooled it
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2025Guideline
- National recommendations for the management of children and young people with IgA vasculitis: a best available evidence, group agreement-based approach.Archives of disease in childhood · 2024Guideline
- IgA Nephropathy: Epidemiology, Outcomes, and Insights for Primary Glomerulonephritides.Journal of clinical medicine · 2026Review
- Recurrent immunoglobulin A vasculitis in children and adolescents: prevalence and associated risk factors.Clinical and experimental pediatrics · 2026Article
- Advances in multi-omics and therapeutic studies of Henoch-Schönlein purpura.Italian journal of pediatrics · 2025Review
- Early discontinuation of steroid treatment in children with abdominal pain due to IgA vasculitis.European journal of pediatrics · 2025Article
- A predictive model to explore risk factors for Henoch-Schönlein purpura nephritis in children: a retrospective cross-sectional study.Frontiers in public health · 2025Article
- Association of Childhood IgA Vasculitis With Allergic Rhinitis and Chronic Rhinosinusitis.Kidney international reports · 2024Article
- Overview of childhood vasculitis.Journal of rheumatic diseases · 2024Review
- Clinical characteristics and risk factors of cardiac involvement in pediatric immunoglobulin A vasculitis: A 7-year retrospective study from a single tertiary medical center.European journal of pediatrics · 2024Article
- A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
- Report of Henoch-Schönlein purpura associated with trastuzumab emtansine.Ecancermedicalscience · 2024Article
- Does age at disease onset affect the clinical presentation and outcome in children with immunoglobulin A vasculitis?Archives of rheumatology · 2023Article
- Henoch-Schönlein purpura in the setting of COVID-19 infection: Two pediatrics cases and review of the literature.Journal of family medicine and primary care · 2023Review
- A case series on recurrent and persisting IgA vasculitis (Henoch Schonlein purpura) in children.Pediatric rheumatology online journal · 2023Article
- Henoch-Schönlein purpura with antecedent allergic diseases in a 4-year-old child: a case report.Annals of medicine and surgery (2012) · 2023Article
- Risk factors associated with recurrence of Henoch-Schonlein purpura: a retrospective study.Frontiers in pediatrics · 2023Article
- Prediction of renal damage in children with IgA vasculitis based on machine learning.Medicine · 2022Article
- Association between common laboratory indices and IgAV recurrence in children.BMC pediatrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recurrence rate of Henoch-Schönlein purpura (HSP) is 2.7%-30%, with varied average intervals between the first and second episodes. Few studies have explored the incidence and risk factors for recurrent HSP.
methodsWe used a 16-year nationwide database to analyze the incidence of recurrent HSP. Patients with HSP were identified, and risk factors for recurrent HSP were explored. Kaplan-Meier and Cox regression model analyses were performed, and covariates were adjusted in the multivariate model.
resultsFrom January 1, 1997 to December 31, 2012, among 2,886,836 individuals in the National Health Insurance Research Database, 1002 HSP patients aged < 18 years were identified. Among them, 164 had ≥2 HSP episodes (recurrence rate, 16.4%; incidence of recurrent HSP, 7.05 per 100 person-years); 83.6% patients with one HSP episode remained free of secondary HSP. The average time intervals between the first and second and second and third HSP episodes were 9.2 and 6.4 months, respectively. After adjusting for demographic parameters, comorbidities, and socioeconomic status, recurrent HSP was found to occur more frequently in patients who had renal involvement (adjusted hazard ratio, 2.41; 95% confidence interval [CI], 1.64-3.54; p < 0.001), were receiving steroid therapy for > 10 days (adjusted hazard ratio, 8.13; 95%CI, 2.51-26.36; p < 0.001), and had allergic rhinitis (adjusted hazard ratio, 1.63; 95%CI, 1.06-2.50; p = 0.026).
conclusionsThe annual incidence of recurrent HSP was low. However, children who had underlying allergic rhinitis, presented with renal involvement, and received steroid treatment for > 10 days should be notified regarding the possibility of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.